A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys by Roest, Annelieke et al.
 1 
 
A comparison of DSM-5 and DSM-IV agoraphobia in the World Mental Health Surveys 
Annelieke M. Roest (PhD)1, Ymkje Anna de Vries (PhD)1, Carmen C. W. Lim (MSc)2, Hans-Ulrich 
Wittchen (PhD)3,4, Dan J. Stein (MD, PhD)5, Tomasz Adamowski (MD, PHD)6, Ali Al-Hamzawi (MD)7, 
Evelyn J. Bromet (PhD)8, Maria Carmen Viana (MD, PhD)9, Giovanni de Girolamo (MD)10, Koen 
Demyttenaere (MD, PhD) 11, Silvia Florescu (MD, PhD)12, Oye Gureje (MD, PhD)13, Josep Maria Haro 
(MD, PhD)14, Chiyi Hu (MD, PhD)15, Elie G. Karam (MD)16, José Miguel Caldas-de-Almeida (MD, PhD)17, 
Norito Kawakami (MD, DMSc)18, Jean Pierre Lépine (MD, HDR)19, Daphna Levinson (PhD)20, Maria E. 
Medina-Mora (PhD) 21, Fernando Navarro-Mateu (MD, PhD)22, Siobhan O’Neill (PhD)23, Maria Piazza 
(ScD, MPH)24, José A. Posada-Villa (MD)25, Tim Slade (PhD)26, Yolanda Torres (MPH, Dra.HC)27, Ronald 
C. Kessler (PhD)28, Kate M Scott (PhD) 29, Peter de Jonge (PhD)1. 
1Department of Developmental Psychology, University of Groningen, Groningen, The Netherlands. 
2Queensland Centre for Mental Health Research, and Queensland Brain Institute, University of 
Queensland, St. Lucia, Queensland, Australia 
3Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, 
Germany. 
4Department of Psychiatry and Psychotherapy, Ludwig-Maximilans-University Munich, Germany. 
5Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, Republic of 
South Africa. 
6Department of Psychiatry, Medical University of Wroclaw, Wroclaw, Poland. 
7College of Medicine, Al-Qadisiya University, Diwania governorate, Iraq. 
8Department of Psychiatry, Stony Brook University School of Medicine, New York, NY, United States.  
9Department of Social Medicine and Post-Graduate Program in Public Health. Psychiatric 
Epidemiology Research Center (CEPEP), Federal University of Espírito Santo (UFES), Vitória, Brazil. 
10IRCCS St John of God Clinical Research Centre, IRCCS Centro S. Giovanni di Dio Fatebenefratelli, 
Brescia, Italy. 
11Department of Psychiatry, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, 
Leuven, Belgium. 
12National School of Public Health, Management and Professional Development, Bucharest, Romania. 
13Department of Psychiatry, University College Hospital, Ibadan, Nigeria. 
14Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain. 
15Shenzhen Insitute of Mental Health & Shenzhen Kangning Hospital, Shenzhen, China. 
16Department of Psychiatry and Clinical Psychology, Faculty of Medicine, Balamand University; 
Department of Psychiatry and Clinical Psychology, St George Hospital University Medical Center; 
Institute for Development Research Advocacy and Applied Care (IDRAAC), Beirut, Lebanon. 
 2 
 
17Lisbon Institute of Global Mental Health and Chronic Diseases Research Center (CEDOC) and 
Department of Mental  Health, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisbon, 
Portugal.  
18Department of Mental Health, School of Public Health, The University of Tokyo, Tokyo, Japan. 
19Hôpital Lariboisière Fernand Widal, Assistance Publique Hôpitaux de Paris, University Paris Diderot 
and Paris Descartes, Paris, France. 
20Ministry of Health Israel, Mental Health Services, Israel. 
21National Institute of Psychiatry Ramon de la Fuente, Mexico. 
22IMIB-Arrixaca;CIBERESP-Murcia; UDIF-SM, Subdirección General de Salud Mental y Asistencia 
Psiquiátrica, Servicio Murciano de Salud, El Palmar (Murcia), Spain. 
23School of Psychology, Ulster University, Northern Ireland. 
24National Institute of Health, Peru, Universidad Cayetano Hereidia, Peru. 
25Colegio Mayor de Cundinamarca University, Bogota, Colombia. 
26National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. 
27Center for Excellence on Research in Mental Health, CES University, Medellin, Colombia. 
28Department of Health Care Policy, Harvard University Medical School, Boston, MA, United States. 
29 Department of Psychological Medicine, University of Otago, Dunedin, Otago, New Zealand. 
 
Short title: Epidemiology of DSM-5 agoraphobia 
Word count: 3726 
Corresponding author: 
Annelieke M. Roest, PhD, 
Assistant Professor 
Faculty of Behavioural and Social Sciences, Department Developmental Psychology 
University of Groningen 
Grote Kruisstraat 2/1 
9712 TS Groningen 
The Netherlands 
 
Acknowledgement information 
This work was carried out in conjunction with the World Health Organization World Mental Health 
(WMH) Survey Initiative which is supported by the National Institute of Mental Health (NIMH; R01 
MH070884), the John D. and Catherine T. MacArthur Foundation, the Pfizer Foundation, the US 
Public Health Service (R13-MH066849, R01-MH069864, and R01 DA016558), the Fogarty 
International Center (FIRCA R03-TW006481), the Pan American Health Organization, Eli Lilly and 
Company, Ortho-McNeil Pharmaceutical, GlaxoSmithKline, and Bristol-Myers Squibb. We thank the 
staff of the WMH Data Collection and Data Analysis Coordination Centres for assistance with 
instrumentation, fieldwork, and consultation on data analysis. None of the funders had any role in 
 3 
 
the design, analysis, interpretation of results, or preparation of this paper. A complete list of all 
within-country and cross-national WMH publications can be found at 
http://www.hcp.med.harvard.edu/wmh/ .The 2007 Australian National Survey of Mental Health and 
Wellbeing was funded by the Australian Government Department of Health and Ageing. The São 
Paulo Megacity Mental Health Survey is supported by the State of São Paulo Research Foundation 
(FAPESP) Thematic Project Grant 03/00204-3. The Colombian National Study of Mental Health 
(NSMH) is supported by the Ministry of Social Protection. The Mental Health Study Medellín – 
Colombia was carried out and supported jointly by the Center for Excellence on Research in Mental 
Health (CES University) and the Secretary of Health of Medellín. The ESEMeD project is funded by the 
European Commission (Contracts QLG5-1999-01042; SANCO 2004123, and EAHC 20081308), the 
Piedmont Region (Italy)), Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Spain (FIS 
00/0028), Ministerio de Ciencia y Tecnología, Spain (SAF 2000-158-CE), Departament de Salut, 
Generalitat de Catalunya, Spain, DIUE de la Generalitat de Catalunya (2017 SGR 452; 2014 SGR 748), 
Instituto de Salud Carlos III (CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP), and other local 
agencies and by an unrestricted educational grant from GlaxoSmithKline. Implementation of the Iraq 
Mental Health Survey (IMHS) and data entry were carried out by the staff of the Iraqi MOH and MOP 
with direct support from the Iraqi IMHS team with funding from both the Japanese and European 
Funds through United Nations Development Group Iraq Trust Fund (UNDG ITF). The Israel National 
Health Survey is funded by the Ministry of Health with support from the Israel National Institute for 
Health Policy and Health Services Research and the National Insurance Institute of Israel.  The World 
Mental Health Japan (WMHJ) Survey is supported by the Grant for Research on Psychiatric and 
Neurological Diseases and Mental Health (H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-
013, H20-KOKORO-IPPAN-009, H25-SEISHIN-IPPAN-006) from the Japan Ministry of Health, Labour 
and Welfare. The Lebanese National Mental Health Survey (L.E.B.A.N.O.N.) is supported by the 
Lebanese Ministry of Public Health, the WHO (Lebanon), National Institute of Health / Fogarty 
International Center (R03 TW006481-01), anonymous private donations to IDRAAC, Lebanon, and 
unrestricted grants from Algorithm, AstraZeneca, Benta, Bellla Pharma, Eli Lilly, GlaxoSmithKline, 
Lundbeck, Novartis, OmniPharma, Pfizer, Phenicia , Servier and UPO. The Mexican National 
Comorbidity Survey (MNCS) is supported by The National Institute of Psychiatry Ramon de la Fuente 
(INPRFMDIES 4280) and by the National Council on Science and Technology (CONACyT-G30544- H), 
with supplemental support from the PanAmerican Health Organization (PAHO). Te Rau Hinengaro: 
The New Zealand Mental Health Survey (NZMHS) is supported by the New Zealand Ministry of 
Health, Alcohol Advisory Council, and the Health Research Council. The Nigerian Survey of Mental 
Health and Wellbeing (NSMHW) is supported by the WHO (Geneva), the WHO (Nigeria), and the 
Federal Ministry of Health, Abuja, Nigeria. The Northern Ireland Study of Mental Health was funded 
by the Health & Social Care Research & Development Division of the Public Health Agency. The 
Shenzhen Mental Health Survey is supported by the Shenzhen Bureau of Health and the Shenzhen 
Bureau of Science, Technology, and Information. The Peruvian World Mental Health Study was 
funded by the National Institute of Health of the Ministry of Health of Peru. The Polish project 
Epidemiology of Mental Health and Access to Care –EZOP Project (PL 0256) was supported by 
Iceland, Liechtenstein and Norway through funding from the EEA Financial Mechanism and the 
Norwegian Financial Mechanism. EZOP project was co-financed by the Polish Ministry of Health. The 
Portuguese Mental Health Study was carried out by the Department of Mental Health, Faculty of 
Medical Sciences, NOVA University of Lisbon, with collaboration of the Portuguese Catholic 
University, and was funded by Champalimaud Foundation, Gulbenkian Foundation, Foundation for 
 4 
 
Science and Technology (FCT) and Ministry of Health. The Romania WMH study projects "Policies in 
Mental Health Area" and "National Study regarding Mental Health and Services Use" were carried 
out by National School of Public Health & Health Services Management (former National Institute for 
Research & Development in Health, present National School of Public Health, Management & 
Professional Development, Bucharest), with technical support of Metro Media Transilvania, the 
National Institute of Statistics – National Centre for Training in Statistics, SC. Cheyenne Services SRL, 
Statistics Netherlands and were funded by Ministry of Public Health (former and present Ministry of 
Health) with supplemental support of Eli Lilly Romania SRL. The Psychiatric Enquiry to General 
Population in Southeast Spain – Murcia (PEGASUS-Murcia) Project has been financed by the Regional 
Health Authorities of Murcia (Servicio Murciano de Salud and Consejería de Sanidad y Política Social) 
and Fundación para la Formación e Investigación Sanitarias (FFIS) of Murcia. The Ukraine Comorbid 
Mental Disorders during Periods of Social Disruption (CMDPSD) study is funded by the US National 
Institute of Mental Health (RO1-MH61905). The US National Comorbidity Survey Replication (NCS-R) 
is supported by the National Institute of Mental Health (NIMH; U01-MH60220) with supplemental 
support from the National Institute of Drug Abuse (NIDA), the Substance Abuse and Mental Health 
Services Administration (SAMHSA), the Robert Wood Johnson Foundation (RWJF; Grant 044708), and 
the John W. Alden Trust. 
"Dr. Stein is supported by the Medical Research Council of South Africa (MRC)" 
Conflict of interest 
In the past 3 years, Dr.  Stein has received research grants and/or consultancy honoraria from 
AMBRF/Foundation for Alcohol Research, Biocodex, Cipla, Lundbeck, National Responsible Gambling 
Foundation, Novartis, Servier, and Sun.  Dr. Demyttenaere has served on advisory boards for, for Eli 
Lilly, Lundbeck, Johnson&Johnson, Servier, Boehringer Ingelheim, Livanova and has research grants 
from Eli Lilly, foundation ‘ga voor geluk’, Fonds voor Wetenschappelijk Onderzoek Vlaanderen. 
 In the past 3 years, Dr. Kessler received support for his epidemiological studies from Sanofi Aventis; 
was a consultant for Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, 
Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life 
Project. Kessler is a co-owner of DataStat, Inc., a market research firm that carries out healthcare 
research. 
Authors Roest, de Vries, de Jonge, Wittchen, Lim, Adamowski, Carmen Viana, Florescu, Kawakami, 
Slade, Torres, Posada-Villa, Lépine, Al-Hamzawi, Levinson,  de Girolamo,  Karam, Elena Medina Mora, 
Gureje, O’Neill, Hu, Piazza, Miguel Caldas-de-Almeida, Maria Haro, Navarro-Mateu, Bromet, and 
Scott do not have conflicts of interest to report.  
 
  
 5 
 
Abstract 
Background: The DSM-5 definition of agoraphobia (AG) as an independent diagnostic entity makes it 
timely to re-examine the epidemiology of AG. Study objective was to present representative data on 
the characteristics of individuals who meet DSM-IV criteria for AG (AG without a history of panic 
disorder [PD] and PD with AG) but not DSM-5 criteria, DSM-5 but not DSM-IV criteria, or both sets of 
criteria.   
Methods: Population-based surveys from the World Mental Health Survey Initiative including adult 
respondents (n=136,357) from 27 countries across the world. The Composite International Diagnostic 
Interview was used to assess AG and other disorders. 
Results: Lifetime and 12-month prevalence estimates of DSM-5 AG (1.5% and 1.0%) were 
comparable to DSM-IV (1.4% and 0.9%). Of respondents meeting criteria in either system, 57.1% met 
criteria in both, while 24.2% met criteria for DSM-5 only and 18.8% for DSM-IV only. Severe role 
impairment due to AG was reported by a lower proportion of respondents who met criteria only for 
DSM-IV AG (30.4%) than those with both DSM-5 and DSM-IV AG (44.0%) (21=4.7;p=.031). The 
proportion of cases with any comorbidity was lower among respondents who met criteria only for 
DSM-IV AG (78.7%) than those who met both sets (92.9%) (21=14.5;p<.001).  
Conclusions: This first large survey shows that, compared to the DSM-IV, the DSM-5 identifies a 
substantial group of new cases with AG, while the prevalence rate remains stable at 1.5%. Severity 
and comorbidity are higher in individuals meeting DSM-5 AG criteria compared with individuals 
meeting DSM-IV AG criteria only.  
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Introduction 
Anxiety disorders are highly prevalent and are major contributors to the burden of disease 
worldwide (Craske et al., 2017; Murray et al., 2012; Whiteford et al., 2013). Agoraphobia (AG) is one 
of the least studied anxiety disorders (Asmundson & Asmundson, 2018), and, especially with the 
introduction of the Diagnostic and Statistical Manual of mental disorders version 5 (DSM-5), there is 
a lack of research focusing on AG including the cross-national epidemiology of AG.  
In the DSM-IV, unlike the International Classification of Diseases (ICD-10), AG was not defined 
as an independent disorder with specific diagnostic criteria, but instead was described as a residual 
group only to be coded in the presence or absence of panic disorder (PD) (i.e. PD with AG (300.21), or 
AG without a history of PD (300.22)) (American Psychiatric Association, 2000). AG was defined as 
anxiety about being in places or situations from which escape might be difficult (or embarrassing) or 
in which help may not be available in the event of having a panic attack or panic-like symptoms. 
These situations had to be avoided, endured with marked distress or with anxiety about having a 
panic attack or panic-like symptoms, or require the presence of a companion (American Psychiatric 
Association, 2000).  
In DSM-5, which was introduced in 2013, AG is defined as a phobic disorder cued by exposure 
to agoraphobic situations. As a result, PD (300.01) and AG (300.22) are unlinked, (American 
Psychiatric Association, 2013; Asmundson, Taylor, & Smits, 2014) consistent with the ICD-10 criteria 
for AG (F40.0) and PD (F41.0) (World Health Organization, 2016). The decision to classify AG as a 
disorder that exists separately from PD was based on studies indicating that a substantial proportion 
of individuals with AG do not have PD (Kessler et al., 2006; Wittchen, Gloster, Beesdo-Baum, Fava, & 
Craske, 2010), and/or PD or panic attacks do not precede AG (as implied in DSM-IV) (Wittchen, Reed, 
& Kessler, 1998; Wittchen et al., 2008; Wittchen et al., 2010). As a result, individuals with AG, but 
without panic-like symptoms, received no formal diagnosis while they showed substantial 
impairment and disability (Wittchen et al., 2010). Further, DSM-5 criterion A is broadened to a fear or 
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avoidance of situations because of thoughts that escape might be difficult or help might not be 
available in the event of developing panic-like symptoms or other incapacitating or embarrassing 
symptoms (e.g., fear of falling in the elderly; fear of incontinence).(American Psychiatric Association, 
2013) This is in line with the ICD criteria, in which AG is understood to be the consequence of a 
broader range of fears (Kogan et al., 2016; Stein, 2012; Wittchen et al., 2010). In order to make a 
better distinction from specific phobia (SP), endorsement of fears from two or more distinct 
situational domains is required in DSM-5. Finally, the DSM-5 criteria for AG are extended compared 
to the DSM-IV criteria to make them more comparable to other (anxiety) disorders, for instance by 
adding persistence and severity requirements (American Psychiatric Association, 2013; Asmundson 
et al., 2014).  
These changes in DSM-5 call for a re-examination of epidemiological data on AG. The 
available information is difficult to evaluate because most studies have examined AG only in 
individuals without a history of PD (Goodwin et al., 2005). As a result, the prevalence of AG (Goodwin 
et al., 2005) and the impairment due to AG has likely been underestimated. Furthermore, there is a 
lack of information on age of onset (AOO) (Wittchen et al., 2010), sociodemographic correlates, and 
comorbidity patterns of AG.(Goodwin et al., 2005). Therefore, the aim of the current study is to 
present and compare data on characteristics of AG according to DSM-5 and DSM-IV criteria (AG 
without a history of PD and PD with AG) from countries in the World Health Organization (WHO) 
World Mental Health (WMH) Survey Initiative.  
Methods 
Survey samples  
Data came from 27 surveys administered in low/lower-middle income countries, upper-
middle income countries, and high-income countries. A total of 136,357 respondents participated. 
Interviews were conducted face-to-face in respondent homes. Adults were selected based on multi-
stage clustered area probability sampling designs designed to generate samples that were 
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representative of the household populations in the countries. The details of within-country sampling 
methods are described in detail elsewhere (Heeringa et al., 2008; Pennell et al., 2008).  
Ethics, consent and permissions 
Informed consent was obtained according to protocols endorsed by local Institutional Review Boards. 
Measures 
Mental disorders 
Mental disorders were assessed with the WHO Composite International Diagnostic Interview 
(CIDI), a fully-structured interview administered by trained lay interviewers, which generates 
diagnoses according to the criteria of the DSM-IV (Kessler & Ustün, 2004). To reduce respondent 
burden, interviews were administered in 2 parts. All respondents completed Part I of the CIDI, 
assessing core mental disorders. Part II, which assessed other disorders and correlates, was 
administered to all respondents with any lifetime Part I diagnosis and a probability subsample of 
other Part I respondents. The Part II data were weighted to adjust for the under-sampling of Part I 
non-cases so that weighted prevalence estimates in the Part II sample are identical to those in the 
Part I sample.  
The disorders include anxiety disorders (PD, AG, generalized anxiety disorder [GAD], social 
anxiety disorder, SP, posttraumatic stress disorder [PTSD]1, separation anxiety disorder), mood 
disorders (major depressive episode and/or dysthymia, bipolar disorder [I, II or subthreshold]), 
disruptive behavior disorders (intermittent explosive disorder, bulimia nervosa, binge eating 
disorder, oppositional defiant disorder, conduct disorder, attention deficit disorder), and substance 
use disorders (alcohol abuse and drug abuse, both with or without dependence). These diagnoses 
have shown generally good concordance with clinical diagnoses based on blinded Structured Clinical 
                                                          
1 In DSM-5 PTSD is no longer listed as an anxiety disorder but instead falls under “trauma- and 
stressor-related disorders”. 
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Interview (SCID) reappraisal (Haro et al., 2006). The AOO of AG was assessed using special recall 
probes that have been shown to yield more plausible distributions of AOO of disorders than 
conventional recall questions (Knäuper, Cannell, Schwarz, Bruce, & Kessler, 1999). 
 For purposes of the current analysis, DSM-5 AG diagnoses were generated retrospectively; a 
series of questions were used to operationalize DSM-5 AG criteria (see supplemental table 1 for the 
DSM-IV and DSM-5 criteria and corresponding CIDI algorithms). We defined three diagnostic groups: 
respondents who only met DSM-IV criteria (AG without a history of PD and PD with AG) (“DSM-IV 
only AG”), respondents who only met DSM-5 criteria (“DSM-5 only AG”), and respondents who met 
both DSM-5 and DSM-IV criteria (“DSM-5 with DSM-IV AG”).  
Impairment  
Severe role impairment in home management, ability to work, ability to form and maintain 
close relationships, and social life was assessed with a modified version of the Sheehan Disability 
Scale (SDS) in respondents with 12-month AG (Leon, Olfson, Portera, Farber, & Sheehan, 1997). The 
response scale for each role domain is from 0-10. Severe impairment was defined as a score ≥7 in at 
least one specific role domain.  Respondents with 12-month AG were also asked how many days in 
the past year they were totally unable to work or carry out their normal activities due to their AG 
(Ormel et al., 2008). Additionally, all Part II respondents were asked how many days in the past 30 
days they were totally unable to work or carry out their normal activities because of any physical or 
mental health problems. Finally, all Part I respondents were asked whether they seriously thought 
about committing suicide in the past 12 months. 
 Treatment 
Respondents were asked whether they ever saw each of a long list of professionals. 
Responses were aggregated into treatment in the specialty mental health sector (e.g. 
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psychiatrist/psychologist), general medical sector (e.g. general practitioner), human services sector 
(e.g. social worker), and complementary and alternative medicine (CAM) sector (e.g. herbalist).  
Socio-demographic correlates 
Factors considered include gender, age cohorts (18-34, 35-49, 50-64, 65+), education level 
(low, low-average, high-average, high), marital status (married, never married, previously married), 
and employment status (employed, student, homemaker, retired, other).  
Statistical analysis 
The actuarial method was used to generate AOO survival curves, and differences in age of 
onset between DSM-IV only AG, DSM-5 only AG, and DSM-5 with DSM-IV AG were tested using 
discrete-time logistic regression in the subsample with DSM-IV or DSM-5 AG. Logistic regression 
analysis was used to evaluate the significance of differences in role impairment, suicidality, 
comorbidity, and treatment between DSM-IV only AG, DSM-5 only AG, and DSM-5 with DSM-IV AG 
cases, and between AG cases and non-cases (where applicable). Logistic regression was also used to 
compare socio-demographic correlates of DSM-IV only AG, DSM-5 only AG, and DSM-5 with DSM-IV 
AG. All analyses were carried out in SAS (9.4). Because the data were clustered and weighted to 
account for unequal selection probabilities, standard errors were estimated using the Taylor series 
linearization method (Wolter, 1985) implemented in SUDAAN (11.0.1) (Research Triangle Institute, 
2002). Significance tests were evaluated using 0.05-level two-sided tests.  
Results 
Prevalence and course of AG 
Lifetime and 12-month prevalence estimates of DSM-IV AG were 1.4% and 0.9%, while those 
of DSM-5 AG were 1.5% and 1.0% (table 1). Consistent with DSM-IV criteria, 100% of cases with DSM-
IV AG experienced fear of panic attacks, compared to 70.2% of cases with DSM-5 AG. Of all 
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respondents with lifetime PD (prevalence of 1.7%), 19.7% met criteria for DSM-IV AG and 18.2% for 
DSM-5 AG (supplemental table 2). 
Of all respondents with lifetime AG, 57.1% (SE=1.3) met criteria for both DSM-5 and DSM-IV 
AG, 18.8% (SE=1.0) only met criteria for DSM-IV, and 24.2% (SE=1.1) only met criteria for DSM-5. 
DSM-5 only lifetime cases had a significantly lower lifetime proportion with PD (9.3%) than DSM-5 
with DSM-IV cases (26.5%) (21=54.3;p<.001) and DSM-IV only cases (19.3%) (21=20.9;p<.001). 
Respondents with DSM-5 with DSM-IV AG had higher persistence (i.e.12-month prevalence among 
lifetime cases; 71.2%) than DSM-IV only (51.9%) (21=47.1;p<.001) and DSM-5 only (64.1%) 
(21=6.2;p=.012) cases. DSM-5 only cases also had a significantly higher persistence than DSM-IV only 
cases (21=18.6;p<.001).  
(Table 1)  
 The median AOO of DSM-5 only AG was 14 years old (interquartile range [IQR] = 9-25), which 
was significantly lower than the median AOO of DSM-IV only AG (median=23, IQR=13-41) and of 
DSM-5 with DSM-IV AG (median=21, IQR=13-39 (2=21.8-24.4;p<.001) (supplemental figure 1). The 
AOO of DSM-IV only AG and DSM-5 with DSM-IV AG did not differ significantly (2=0.3, p=0.55).  
Impairment 
Severe role impairment in the past 12 months was reported by 30.4% of respondents with 
DSM-IV only AG, 43.3% of respondents with DSM-5 only AG, and 44.0% of respondents with DSM-5 
with DSM-IV AG, with a significant difference between DSM-IV only and DSM-5 with DSM-IV AG 
(21=4.7;p=.031). Mean number of days out of role in the past year due to AG was also significantly 
lower among respondents with DSM-IV only AG (29.9) compared with DSM-5 with DSM-IV AG (55.8) 
(21=8.0;p=.005), while that for DSM-5 only AG (40.2) did not differ from DSM-IV only AG 
(21=2.1;p=0.147) or DSM-5 with DSM-IV AG (21=1.7;p=0.190). Although suicidal ideation rates were 
higher for all AG subgroups compared to respondents without AG (1.7%), there were no significant 
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differences in suicidal ideation rates among respondents with DSM-IV only (10.0%), DSM-5 only 
(15.7%), or DSM-5 with DSM-IV (15.8%) AG (table 2).  
(Table 2)  
Comorbidity 
Respondents in all AG subgroups reported higher rates of lifetime and 12-month mental 
disorder comorbidity compared to respondents without AG, except for 12-month substance use 
disorders in the DSM-IV only AG subgroup (21=0.7;p=0.39) (table 3). Comorbidity rates were 
significantly lower for respondents with DSM-IV only (3.5–78.7%) than for respondents with DSM-5 
with DSM-IV AG (8.1–92.9%), except for 12-month disruptive behavior disorders and 12-month and 
lifetime substance use disorders. Respondents with DSM-5 only AG did not have a significantly lower 
rate of comorbidity (12.6–88.7%) than respondents with DSM-5 with DSM-IV AG for any disorder 
category except any lifetime disorder (21=4.4;p=0.036). Also, they reported a significantly higher 
rate of comorbidity than respondents with DSM-IV only AG for 12-month anxiety disorder 
(21=6.9;p=0.009) and lifetime anxiety disorders (21=7.1;p=0.008). 
(Table 3) 
Treatment  
Respondents in all AG subgroups were more likely to receive any lifetime treatment (31.0-
52.8%) than respondents without AG (8.4%), but respondents with DSM-IV only AG were significantly 
less likely than respondents with DSM-5 with DSM-IV AG to receive any lifetime treatment (table 4). 
They were also less likely than respondents with DSM-5 with DSM-IV AG to receive 12-month 
specialty mental health care or any 12-month treatment but not less likely to receive 12-month 
general medical care, human services, or CAM treatment. Respondents with DSM-5 only AG were 
significantly less likely to receive any type of treatment than respondents with DSM-5 with DSM-IV 
AG with the exception of human services or CAM treatment. There were no significant differences in 
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treatment rates between respondents with DSM-IV only AG and those with DSM-5 only AG, with the 
exception of lifetime human services (21=5.5,p=.019). 
(Table 4) 
Sociodemographic correlates 
Younger age, female gender, lower education, not being married, and unemployment were 
associated with 12 month- and lifetime AG, although some associations did not reach statistical 
significance for one or more of the diagnostic groups (table 5). As a group, the ORs for age cohort for 
DSM-5 only AG differed from the ORs for DSM-5 with DSM-IV AG, yet p-values for comparing ORs 
between specific age groups were not statistically significant. Compared to high education, odds for 
respondents with low, low-average, and high-average education, were particularly high for DSM-IV 
only AG.  
(Table 5) 
Discussion 
This study is the first to present representative data for DSM-5 compared to DSM-IV AG (AG 
without a history of PD and PD with AG) from countries across the world. Lifetime and 12-month 
prevalence estimates of DSM-5 AG were 1.5% and 1.0%, while those of DSM-IV AG were 1.4% and 
0.9%. Hence, there was no marked shift in AG prevalence from DSM-IV to DSM-5. However, only 
57.1% of respondents with AG met criteria in both diagnostic systems, with 18.8% of AG cases 
meeting criteria only for DSM-IV and 24.2% meeting criteria only for DSM-5. Compared to DSM-IV 
AG, DSM-5 AG was characterized by a higher persistence of AG and higher rates of severe role 
impairments, treatment-seeking, and mental disorder comorbidity.   
 Several sociodemographic correlates of AG were identified, consistent with other studies of 
AG and PD (Andrews & Slade, 2002; Jonge et al., 2016). Although some quantitative differences were 
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found for associations between sociodemographic factors and diagnostic subgroups, the general 
patterns were comparable, with younger age, female gender, lower education, not being married, 
and unemployment being associated with AG.  
Although our prevalence rates are comparable to the reported prevalence of 12-month DSM-
IV AG without a history of PD across European countries (1.3%) (Goodwin et al., 2005), they are in 
contrast with the extremely low prevalence rate of 0.05% for 12-month DSM-IV AG without a history 
of PD found in a nationally representative study in the US, which may (partly) result from the 
exclusion of lifetime PD cases and a clinical significance criterion used in that study (Grant et al., 
2006). Although our 12-month prevalence rate of DSM-IV AG increased by including AG with PD, it is 
interesting to note that 75% of respondents with 12-month DSM-IV AG did not have a history of PD. 
This percentage is comparable to that found for 12-month AG in an Australian survey, in which 64% 
did not have a history of PD (Andrews & Slade, 2002), and clearly supports the decision made in 
DSM-5 to separate AG from PD.  
The relatively stable prevalence rates for DSM-IV and DSM-5 AG may result from a 
broadening of the range of fears beyond a fear of panic attacks or panic-like symptoms in DSM-5 on 
the one hand, while increasing the strictness of the (severity) criteria on the other hand. None of the 
respondents with DSM-5 only AG reported fear of panic attacks in the feared situations. In addition, 
the percentage of respondents reporting severe role impairment, and the mean number of days out 
of role in the past year due to AG, were significantly lower for respondents with DSM-IV only 
compared to respondents with 12-month DSM-5 with DSM-IV AG. However, the mean number of 
days out of role in the past 30 days for any health reason, and 12-month suicidal ideation, were 
increased for all AG subgroups compared to respondents without AG. In addition, respondents with 
DSM-IV only AG also had increased treatment and mental comorbidity rates compared to 
respondents without AG. Although these results indicate that individuals who meet DSM-IV but not 
DSM-5 AG criteria also suffer from clinically significant symptoms including impairment, this suffering 
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may for a large part be the result of comorbid mental disorders. However, we cannot exclude the 
possibility that a small group of individuals who experience severe distress or impairment are left 
without a diagnosis as a result of the changes in DSM-5, but the population prevalence rate of 
lifetime DSM-IV only AG without mental disorder comorbidity is very low, namely 0.08%. 
We found a particularly low median AOO for DSM-5 only AG. This result adds to previous 
studies that showed that AG is not a mere consequence of PD (Wittchen et al., 1998; Wittchen et al., 
2008) and that the median AOO of AG appears to be lower than the AOO of PD (Wittchen et al., 
1998). The current study therefore confirms that DSM-5 AG is more comparable to other phobic 
disorders, which have early onsets as well (Kessler et al., 2005; Stein et al., 2017). Identifying 
individuals who suffer from AG at a younger age may lead to earlier AG focused treatment and 
thereby has the potential to prevent disorder progression and development of comorbidity (Jones, 
2013; Kessler et al., 2005).  
One of the reasons for the controversy whether AG can be regarded as a disorder that is 
independent of PD (Grant et al., 2006; Wittchen et al., 1998; Wittchen et al., 2008) is that AG without 
a history of PD is not typically seen in clinical studies and it has been suggested that many individuals 
diagnosed with AG in epidemiological studies actually suffer from SP (Horwath, Lish, Johnson, Hornig, 
& Weissman, 1993). However, another study validated the existence of AG in the absence of panic 
attacks in a survey through a re-evaluation with structured interviews (Faravelli, Cosci, Rotella, 
Faravelli, & Dell'Osso, 2008). A better distinction between SP and AG probably reflects better 
measurements of AG in recent surveys (Andrews & Slade, 2002; Wittchen et al., 2010). For example, 
in order to meet criteria for AG in this study, agoraphobic anxiety had to apply to at least two 
situations. The low percentage of AG cases seen in clinical care might also be the result of these 
individuals being less likely to seek help (Andrews & Slade, 2002; Wittchen et al., 1998), potentially as 
a result of avoidance behaviour (Andrews & Slade, 2002). Indeed, the percentage of individuals with 
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AG seeking treatment was lower compared to rates for individuals with PD in the WMH surveys (de 
Jonge, Roest, Lim, Levinson, & Scott, 2018; Roest et al., 2018).  
A previous review article concluded that AG should be seen as a disorder independent from 
PD based on data from community samples on prevalence rates, temporal relationships of AG, panic 
attacks, and PD, and impairment associated with AG without panic attacks (Wittchen et al., 2010). 
Greene and Eaton (2016) also argued that AG is a diagnostic entity that should be separated from PD. 
By examining multivariate comorbidity patterns of PD and AG, the authors showed that AG could be 
categorized as a fear disorder, while PD is more strongly related to distress disorders, such as 
depression (Greene & Eaton, 2016). Yet, evidence is lacking for specific genetic underpinnings of AG 
(Wittchen et al., 2010) and for differential treatment effects; the latter may result from a lack of 
treatment studies focusing on patients with AG without PD (Bandelow, 2017; Wittchen et al., 2010). 
To our knowledge only one other study examined the effect of changes from DSM-IV to DSM-5 
criteria for AG. This study examined the effect of the more stringent criterion A in DSM-5 
(endorsement of fears from multiple distinct situational domains) on the prevalence rate of AG in 
children and adolescents seeking anxiety treatment (Cornacchio, Chou, Sacks, Pincus, & Comer, 
2015). Authors concluded that this adaptation may be too strict for youth, because a substantial 
proportion (25%) of individuals no longer met criteria for AG, despite being more similar regarding 
symptomatology and impairment, to individuals who met the new AG criteria than to individuals with 
SP (Cornacchio et al., 2015). Whether and how the changes in DSM-5 criteria will affect clinical 
treatment is yet unclear (Bandelow, 2017), however additional research into DSM-5 AG in general 
(Wittchen et al., 2010), and specifically the treatment of DSM-5 AG without PD or panic attacks is 
warranted, especially given the high persistence of DSM-5 AG shown in the current study.  
A strength of the current study is the use of data from the WMH surveys. The WHO WMH 
Survey Initiative provides a unique opportunity to examine the cross-national epidemiology of AG 
because it included data from countries with different income ranges. The numbers of respondents 
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were large enough to examine both lifetime and 12-month AG and compare diagnostic groups based 
on DSM-IV and DSM-5 criteria, although not large enough to additionally examine differences 
between countries. Another strength is that the surveys used a common protocol and instrument to 
assess AG separately from PD. However, this study also has a number of limitations. First, although 
we examined AG using both DSM-IV and DSM-5 criteria, the algorithm was modified in retrospect, as 
was the case in other reports on DSM-5 criteria for GAD, PTSD, and substance use disorder in the 
WMH surveys (Ruscio et al., 2017; Slade et al., 2016; Stein et al., 2014). As a result, the CIDI questions 
do not match all DSM-5 criteria perfectly. Although this could have caused misclassification in some 
cases concerning the DSM-5 diagnosis of AG, we do not expect this to have a large impact on the 
comparisons between results for the AG subgroups, since the criteria based on the CIDI questions 
were sometimes less and sometimes more strict than original DSM-5 criteria. Second, because the 
data are cross-sectional, AOO is reported retrospectively and the indicator of AG persistence is a 
proxy indicator.  
In conclusion, this study is the first to investigate and compare the epidemiology of AG 
according to the DSM-5 and the DSM-IV. Results show that the DSM-5 criteria may be an 
improvement over the DSM-IV criteria as the DSM-5 identifies individuals with a higher disorder 
persistence, severity, and comorbidity and help-seeking rates, while the global lifetime and 12-month 
prevalence rates remained relatively constant.  
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